Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448).
Sign Up to like & getrecommendations! Published in 2022 at "ACS medicinal chemistry letters"
DOI: 10.1021/acsmedchemlett.2c00213
Abstract: Lazertinib (YH25448) is a novel third-generation tyrosine kinase inhibitor (TKI) developed as a treatment for EGFR mutant non-small cell lung cancer. To better understand the nature of lazertinib inhibition, we determined crystal structures of lazertinib… read more here.
Keywords: lazertinib yh25448; lazertinib; inhibition; chemistry ... See more keywords